Cointime

Transcenta

company

About

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.

  • 251 - 500

Highlights

Total Funding Amount
$342M
Funding Rounds
4
Investors
3
Investments
1

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$137M
Industries
Biopharma,Biotechnology
Founded date
Jan 1, 2019
Number Of Employee
251 - 500
Operating Status
Active

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$342M
Transcenta has raised a total of $342M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 29, 2021 Post-IPO Equity — 2 ARCH Venture Partners
Lilly Asia Ventures 		— Detail
Dec 23, 2020 Series C $105M 1 — — Detail
Jan 8, 2020 Series B $100M 3 ARCH Venture Partners — Detail
Jan 2, 2019 Series Unknown $137M 2 ARCH Venture Partners
Lilly Asia Ventures 		— Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Transcenta has made 1 investments. Their most recent investment was on Oct 16, 2017, when Digital Asset raised $40M.
Date Company Name
Round Money Raised Industry Lead Investor
Oct 16, 2017 Digital Asset
Series B $40M Blockchain —

Investors

Number of Lead Investors
Number of Investors
5
3
Transcenta is funded by 3 investors. ARCH Venture Partners and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Yes Post-IPO Equity
Lilly Asia Ventures Yes Post-IPO Equity
Yipu Capital — Series B
Cointime
เนื้อหา
บริษัท